Antimicrobial consumption, costs and resistance patterns: a two year prospective study in a Romanian intensive care unit

BMC Infectious Diseases
Carmen AxenteL Baditoiu

Abstract

Due to the vulnerable nature of its patients, the wide use of invasive devices and broad-spectrum antimicrobials used, the intensive care unit (ICU) is often called the epicentre of infections. In the present study, we quantified the burden of hospital acquired pathology in a Romanian university hospital ICU, represented by antimicrobial agents consumption, costs and local resistance patterns, in order to identify multimodal interventional strategies. Between 1st January 2012 and 31st December 2013, a prospective study was conducted in the largest ICU of Western Romania. The study group was divided into four sub-samples: patients who only received prophylactic antibiotherapy, those with community-acquired infections, patients who developed hospital acquired infections and patients with community acquired infections complicated by hospital-acquired infections. The statistical analysis was performed using the EpiInfo version 3.5.4 and SPSS version 20. A total of 1596 subjects were enrolled in the study and the recorded consumption of antimicrobial agents was 1172.40 DDD/ 1000 patient-days. The presence of hospital acquired infections doubled the length of stay (6.70 days for patients with community-acquired infections versus 16.0...Continue Reading

References

Jun 28, 2005·Médecine et maladies infectieuses·F M MacKenzie
Jan 1, 2008·International Journal of Antimicrobial Agents·Dominique M VandijckJohan M Decruyenaere
Sep 9, 2008·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Haridimos MarkogiannakisStilianos Katsaragakis
Nov 25, 2011·Annals of Intensive Care·Nele BrusselaersStijn Blot
Feb 27, 2013·Revista brasileira de anestesiologia·Necla DereliFiliz Koç
Jun 26, 2013·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Fernando Góngora RubioMargarete Teresa Gottardo Almeida
Jul 10, 2013·Antimicrobial Agents and Chemotherapy·Milena McLaughlinMarc H Scheetz
Sep 6, 2013·Annals of Clinical Microbiology and Antimicrobials·Hamdi SözenMurat Sahan
Nov 19, 2013·Antimicrobial Resistance and Infection Control·Angela HuttnerDidier Pittet
May 29, 2015·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H AkhloufiA Verbon

❮ Previous
Next ❯

Software Mentioned

EpiInfo
SPSS

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Related Papers

Einstein
Camila Delfino Ribeiro da Silva, Moacyr Silva Júnior
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases
Ana Milda Karsten BaumgartAlessandro Conrado de Oliveira Silveira
© 2022 Meta ULC. All rights reserved